• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌的细胞动力学模型及其在临床数据和个体患者中的应用。

A cell kinetics model for prostate cancer and its application to clinical data and individual patients.

机构信息

Los Alamos National Laboratory, Los Alamos, NM 87545, USA.

出版信息

J Theor Biol. 2010 May 21;264(2):420-42. doi: 10.1016/j.jtbi.2010.02.023. Epub 2010 Feb 20.

DOI:10.1016/j.jtbi.2010.02.023
PMID:20176031
Abstract

A cell kinetics model is developed to describe the evolution of prostate cancer (PC) from diagnosis to PC specific death. Such a model can be used to estimate an individual's eventual outcome and thus to inform decisions about therapy. To describe the observed clinical progression, the model must postulate three PC cell populations that are (1) local to the prostate and sensitive to hormones, (2) regional and hormone sensitive, and (3) systemic and hormone resistant. A set of coupled first-order differential equations describes the exponential growth of a PC tumor as well as its transformation from a local to systemic disease. The time dependence of the solutions is scaled to the doubling time of the prostate specific antigen (PSADT) because it characterizes the tumor growth for the individual. The conversion from local to systemic cell populations is described with a parameter alpha that can be associated with the Gleason score. The model also has three critical cell populations that describe (1) the initiation of the non-local populations, (2) the saturation level of the local tumor, and (3) the cell count likely to cause PC specific death. These parameters are calibrated by reproducing published PC clinical data and survival tables. The model is then applied to individuals with complete PC diagnostic data in order to calculate the progression to PC specific death. One man has early stage PC as described in the 'vignette' patient of Walsh et al. (2007. N. Engl. J. Med. 357, 2696-2705). The second man has a more serious condition and has undergone both local and systemic treatments. Unfortunately, I am that patient.

摘要

建立了一个细胞动力学模型来描述前列腺癌(PC)从诊断到 PC 特异性死亡的演变。这样的模型可以用来估计个体的最终结果,从而为治疗决策提供信息。为了描述观察到的临床进展,该模型必须假设三种 PC 细胞群体,分别是(1)局部前列腺且对激素敏感,(2)区域性且对激素敏感,以及(3)系统性且对激素耐药。一组耦合的一阶微分方程描述了 PC 肿瘤的指数增长及其从局部疾病向系统性疾病的转变。解决方案的时间依赖性被缩放至前列腺特异性抗原(PSA)倍增时间(PSADT),因为它可以为个体的肿瘤生长提供特征。从局部到系统性细胞群体的转换用参数α来描述,该参数α可以与 Gleason 评分相关联。该模型还有三个关键的细胞群体,分别描述了(1)非局部细胞群体的起始,(2)局部肿瘤的饱和水平,以及(3)可能导致 PC 特异性死亡的细胞计数。通过重现发表的 PC 临床数据和生存表,对这些参数进行了校准。然后,该模型被应用于具有完整 PC 诊断数据的个体,以计算向 PC 特异性死亡的进展。一个人患有 Walsh 等人描述的早期 PC(2007. N. Engl. J. Med. 357, 2696-2705)的 vignette 患者。第二个男人的病情更严重,已经接受了局部和全身治疗。不幸的是,我就是那个病人。

相似文献

1
A cell kinetics model for prostate cancer and its application to clinical data and individual patients.前列腺癌的细胞动力学模型及其在临床数据和个体患者中的应用。
J Theor Biol. 2010 May 21;264(2):420-42. doi: 10.1016/j.jtbi.2010.02.023. Epub 2010 Feb 20.
2
Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.前列腺特异性抗原倍增时间可预测接受联合放疗和激素治疗的前列腺癌患者的临床结局和生存率。
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):456-62. doi: 10.1016/j.ijrobp.2005.03.008.
3
Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.在血清前列腺特异性抗原水平检测不到或较低的情况下前列腺癌的进展
Cancer. 2007 Jan 15;109(2):198-204. doi: 10.1002/cncr.22372.
4
Prognostic markers in clinically localized prostate cancer.临床局限性前列腺癌的预后标志物
Tech Urol. 1998 Mar;4(1):35-42.
5
Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.Ki-67在筛查发现的低级别、低分期前列腺癌中的情况,与前列腺特异性抗原倍增时间、Gleason评分及根治性前列腺切除术后前列腺特异性抗原复发的关系
Scand J Urol Nephrol. 2009;43(1):12-8. doi: 10.1080/00365590802469543.
6
Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.采用分泌粒细胞巨噬细胞集落刺激因子的异基因细胞免疫疗法治疗前列腺癌生化复发
J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048. Epub 2008 Sep 17.
7
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.治疗后前列腺特异性抗原倍增时间作为前列腺癌特异性生存的替代终点:放射治疗肿瘤学组92-02方案分析
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71. doi: 10.1016/j.ijrobp.2006.06.017. Epub 2006 Sep 18.
8
Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.基于前列腺癌根治术后早期前列腺特异性抗原复发结果预测长期前列腺特异性抗原结局的准确性。
J Urol. 2001 Dec;166(6):2198-201.
9
Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.CAPRA评分预测根治性前列腺切除术后无生化复发生存率的有效性。来自欧洲1296例患者的多中心调查结果。
J Urol. 2007 Nov;178(5):1957-62; discussion 1962. doi: 10.1016/j.juro.2007.07.043. Epub 2007 Sep 17.
10
Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.前列腺特异性抗原倍增时间作为前列腺癌的预后标志物
Nat Clin Pract Urol. 2005 Oct;2(10):482-91. doi: 10.1038/ncpuro0321.

引用本文的文献

1
Improving neuroendocrine tumor treatments with mathematical modeling: lessons from other endocrine cancers.用数学建模改善神经内分泌肿瘤治疗:来自其他内分泌癌的经验教训。
Endocr Oncol. 2025 Feb 5;5(1):e240025. doi: 10.1530/EO-24-0025. eCollection 2025 Jan.
2
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.在接受前列腺切除术或挽救性放疗治疗前列腺癌后 PSA 升高的患者中,用基于树突细胞的主动细胞免疫疗法(DCVAC/PCa)进行的 I/II 期试验。
Cancer Immunol Immunother. 2018 Jan;67(1):89-100. doi: 10.1007/s00262-017-2068-x. Epub 2017 Sep 25.
3
Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.
对接受间歇性雄激素抑制治疗的前列腺癌患者 PSA 动力学的定量数学建模。
J Mol Cell Biol. 2012 Jun;4(3):127-32. doi: 10.1093/jmcb/mjs020. Epub 2012 May 4.
4
Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer.利用肿瘤动力学来阐明前列腺癌生化复发列线图中观察到的可变性。
Prostate. 2012 Feb;72(3):280-90. doi: 10.1002/pros.21429. Epub 2011 May 31.